Shattuck Labs discontinues SL-172154, cuts 40% workforce, pivots to DR3 antagonist SL-325

Shattuck Labs, Inc.

Discontinued SL-172154 after interim OS data showed only modest improvement vs azacitidine monotherapy in TP53m AML/HR-MDS.
Plans to focus on SL-325, a first-in-class DR3 antagonist antibody for IBD; IND filing expected Q3 2025.
Approximately 40% workforce reduction; expects restructuring charges of $1.5M-$1.75M in Q4 2024.
Cash runway extended into 2027, with $105.3M cash, cash equivalents and investments as of June 30, 2024.
Mutually terminated collaboration with Ono Pharmaceutical; no future reimbursements, milestones, or royalties.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.